Clinical Trials Search
Clinical Trial 19101
Interventions:BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Study Type: Treatment
Phase of Study: Phase I/II
- Scott Antonia
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
To investigate the anti-tumor activity of BMS-986205 administered in combination with nivolumab in distinct cohorts of subjects with advanced malignant tumors. To evaluate the safety and tolerability of BMS-986205 in combination with nivolumab in subjects with advanced malignant tumors. Secondary Objectives: To characterize the pharmacokinetics (PK) of BMS-986205 administered alone and in combination with nivolumab. To investigate the anti-tumor activity of BMS-986205 administered in combination with nivolumab in dose escalation and clinical pharmacology substudies. To characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab. To characterize the immunogenicity of nivolumab when administered in combination with BMS-986205.